Global recognition for Prescient Chief Scientific Officer

Company News

Prescient Therapeutics (ASX: PTX) has announced that its Chief Scientific Officer and co-inventor of PTX's technologies, Professor Said Sebti, has been named one of the Top 20 Translational Researchers in the world by leading science publication, Nature.

Professor Sebti has been ranked on the list alongside Nobel laureate Dr David Baltimore. The list is compiled by patent analytics firm IP Checkups and follows its examination of last year's most active scientists for patenting.

Scientists are included on the list following examination of each researcher's most cited patent from the previous five years and their 'H index', which is a score based on the impact of the published work.

According to Prescient Therapeutics' Managing Director, Dr Rob Crombie, "We are privileged to have such a distinguished scientist as Professor Sebti as part of our team. He has done seminal work in targeting Ras, AKT and other key cancer pathways and this distinction recognises his important contribution in these areas.

"Furthermore, the fact Professor Sebti's work is so frequently cited also demonstrates globally the relevance and importance of our strategic approach to targeting the AKT and Ras pathways to combat cancer."